Avalanche Biotechnologies (AAVL US)

Adverum Biotechnologies, Inc. operates as a biotechnology company. The Company focuses on targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, and wet age-related macular degeneration.